Skip to content
2000
Volume 26, Issue 2
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Metals are vital cellular elements necessary for multiple indispensable biological processes of living organisms, including energy transduction and cell proliferation. Interestingly, alterations in metal levels and also changes in the expression of proteins involved in metal metabolism have been demonstrated in a variety of cancers. Considering this and the important role of metals for cell growth, the development of drugs that sequester metals has become an attractive target for the development of novel anti-cancer agents. Interest in this field has surged with the design and development of new generations of chelators of the thiosemicarbazone class. These ligands have shown potent anticancer and anti-metastatic activity in vitro and in vivo. Due to their efficacy and safe toxicological assessment, some of these agents have recently entered multi-center clinical trials as therapeutics for advanced and resistant tumors. This review highlights the role and changes in homeostasis of metals in cancer and emphasizes the pre-clinical development and clinical assessment of metal ion-binding agents, namely, thiosemicarbazones, as antitumor agents.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867324666170705120809
2019-01-01
2025-04-09
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867324666170705120809
Loading

  • Article Type:
    Review Article
Keyword(s): anti-cancer drugs; cancer; chelators; copper and zinc; iron; Metals
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test